<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001637</url>
  </required_header>
  <id_info>
    <org_study_id>Longvida</org_study_id>
    <secondary_id>919820711140</secondary_id>
    <nct_id>NCT01001637</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease</brief_title>
  <official_title>Phase II Study of Curcumin Formulation (Longvida) or Placebo on Plasma Biomarkers and Mental State in Moderate to Severe Alzheimer's Disease or Normal Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaslok Hospital and Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmanza Herbal Pvt Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Verdure Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaslok Hospital and Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Curcumin is shown to impact several different pathways of neuroprotection, however clinical
      trials have not shown positive results, due to the poor bioavailability of curcumin. This
      study is designed to determine efficacy and safety of high-bioavailability curcumin
      formulation (Longvida) in subjects with Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Curcumin is a polyphenolic molecule that comprises approximately 3-5% of turmeric (Curcuma
      longa) root, giving the spice its characteristic yellow color. Because of its
      anti-inflammatory, anti-amyloid, and antioxidant properties, curcumin has shown positive
      effects in animal models of Alzheimer's disease (AD). However, a six month human study was
      conducted with unformulated curcumin showing insignificant trends, due to limited
      bioavailability and brain permeability of unformulated curcumin. In animal models of AD, oral
      dosing of solid-lipid curcumin particle (SLCP or Longvida) significantly reduced memory
      deficit and impacted biomarkers better than unformulated curcumin. This study is to determine
      the potential efficacy and safety of highly absorbed SLCP curcumin in subjects with AD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if curcumin formulation affects mental capacity in Alzheimer's patients based on mental exams</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if curcumin formulation changes blood concentrations of amyloid-beta</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin Formulation</intervention_name>
    <description>2000mg or 3000mg daily BID</description>
    <arm_group_label>curcumin</arm_group_label>
    <other_name>Longvida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female age ≥ 50.

          -  Diagnosed with probable AD using NINDS-ADRDA research criteria. MMSE score ≥5 and ≤20.

          -  No history of significant psychiatric or non-AD neurological disease.

          -  An available caregiver to monitor and administer medication and to accompany the
             subject to every clinical visit.

          -  On stable doses of concomitant medications for at least one month prior to starting
             study medication.

        Exclusion Criteria:

          -  Current or recent major psychiatric illness that meets DSM-IV criteria (i.e. bipolar
             disorder, schizophrenia).

          -  Significant uncontrolled systemic illness (i.e. chronic renal failure, chronic liver
             disease, poorly controlled diabetes, or poorly controlled congestive heart failure).

          -  Recent history of gastrointestinal bleeding or ulceration.

          -  Alcoholism or substance abuse within the past year per DSM-IV criteria.

          -  Familial, autosomal dominant Alzheimer's disease due to a mutation in a known gene
             (Presenilin-1, Presenilin-2, or Amyloid Precursor Protein).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fali Poncha, DM neuro</last_name>
    <role>Study Director</role>
    <affiliation>Jaslok Hospital and Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fali Poncha, MD</last_name>
    <phone>9820711140</phone>
    <email>fali@rediffmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitin Kochar, MD</last_name>
    <phone>9819702151</phone>
    <email>nitinkochar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jaslok Hospital and research centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fali Poncha, MD, DM Neuro</last_name>
      <phone>9820711140</phone>
      <email>fali@rediffmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nitin Kochar, MD</last_name>
      <phone>9819702151</phone>
      <email>nitinkochar@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fali Poncha, DM neuro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <last_update_submitted>October 23, 2009</last_update_submitted>
  <last_update_submitted_qc>October 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Fali Poncha</name_title>
    <organization>Jaslok Hospital and Research centre</organization>
  </responsible_party>
  <keyword>curcumin</keyword>
  <keyword>alzheimer's</keyword>
  <keyword>longVida</keyword>
  <keyword>dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

